You are here
November 23, 2015
Comparing blood pressure control targets
At a Glance
Adults treated at a target blood pressure level lower than commonly recommended had a reduced risk of cardiovascular disease and death.
While there were some adverse effects with the lower target, study results suggest that the benefits outweighed the risks.
Blood pressure is the force of blood pushing against the walls of the arteries. High blood pressure, or hypertension, occurs when this force is too high. About 1 in 3 U.S. adults has hypertension. The condition itself usually causes no symptoms, but it can damage the heart, blood vessels, kidneys, and other parts of the body if left untreated.
Blood pressure is typically given as 2 numbers, such as 110/70 millimeters of mercury (mm Hg). The first number is systolic pressure, which is measured as the heart beats to pump blood. The second is diastolic pressure, which is measured when the heart is at rest between beats.
NIH’s National Heart, Lung, and Blood Institute (NHLBI), along with other NIH components, sponsored a large clinical study to determine whether treating people with hypertension to a target systolic blood pressure of less than 120 mm Hg (intensive treatment) would be more beneficial than targeting a level of 140 mm Hg (standard treatment).
Researchers enrolled more than 9,300 participants, age 50 and older, from 102 medical centers and clinical practices throughout the U.S. and Puerto Rico. The participants had increased cardiovascular risk, but didn’t have diabetes. About 36% were women, 58% were white, 30% were African-American, and 11% were Hispanic. Approximately 28% were 75 or older, and 28% had chronic kidney disease.
Participants who were randomly assigned to the target of less than 120 mm Hg received 3 medications on average, while those whose target was less than 140 mm Hg received about 2. The researchers monitored a variety of cardiovascular disease outcomes.
NIH stopped the intervention in August 2015—a year earlier than planned and after a median follow-up of about 3 years—when it became apparent that the more intensive intervention was beneficial. The findings were published online in the New England Journal of Medicine on November 9, 2015.
The researchers found that targeting a systolic blood pressure of less than 120 mm Hg reduced rates of cardiovascular events, such as heart attack and heart failure, as well as stroke, by 25% compared to the 140 mm Hg target. The more intensive treatment also reduced the risk of death by 27%.
Certain types of serious consequences were more common in the group undergoing the intensive treatment. These included low blood pressure, fainting, electrolyte abnormalities, and acute kidney damage. However, rates of other serious adverse events that may be associated with lower blood pressure—such as slow heart rate and falls with injuries—were similar in both groups.
“Although the study provides strong evidence that a lower blood pressure target saves lives in people who are at higher risk for cardiovascular events, patients and their health care providers may want to wait to see how guideline groups incorporate this study and other scientific reports into any future hypertension guidelines,” says study co-author Dr. Lawrence Fine of NHLBI. “In the meantime, patients should talk to their health care providers to determine whether this lower goal is best for their individual care.”
The researchers are continuing to assess the effects of the treatments on kidney disease, cognitive function, and dementia.
- Program Improves Blood Pressure Control
- Structure of a Key Blood Pressure Regulator
- Genes that Influence Blood Pressure
- High Blood Pressure
- Love Your Heart—Take Steps To Reduce Heart Risks
- Systolic Blood Pressure Intervention Trial (SPRINT) Overview
Reference: A Randomized Trial of Intensive versus Standard Blood-Pressure Control. SPRINT Research Group. N Engl J Med. 2015 Nov 9. [Epub ahead of print]. doi: 10.1056/NEJMoa1511939. PMID: 26551272.
Funding: NIH’s National Heart, Lung, and Blood Institute (NHLBI), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Aging (NIA), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Advancing Translational Sciences (NCATS), National Institute of General Medical Sciences (NIGMS), and National Institute of Dental and Craniofacial Research (NIDCR); and the Department of Veterans Affairs.